Cargando…

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy

In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore determined PDL1 and PDL2 expression on DC populations in bone marrow of patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sponaas, Anne-Marit, Moharrami, Neda Nejati, Feyzi, Emadoldin, Standal, Therese, Holth Rustad, Even, Waage, Anders, Sundan, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596870/ https://www.ncbi.nlm.nih.gov/pubmed/26444869 http://dx.doi.org/10.1371/journal.pone.0139867

Ejemplares similares

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients
por: Sponaas, Anne-Marit, et al.
Publicado: (2018)

The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma
por: Sponaas, Anne M, et al.
Publicado: (2015)

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
por: Sponaas, Anne Marit, et al.
Publicado: (2021)

Monitoring multiple myeloma by quantification of recurrent mutations in serum
por: Rustad, Even Holth, et al.
Publicado: (2017)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
por: Misund, Kristine, et al.
Publicado: (2022)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
por: Yang, Rui, et al.
Publicado: (2020)

Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
por: Våtsveen, Thea Kristin, et al.
Publicado: (2016)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells
por: Nokhbehsaim, Marjan, et al.
Publicado: (2013)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
por: Safi, Mohammed, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

PDL1 Regulation by p53 via miR-34
por: Cortez, Maria Angelica, et al.
Publicado: (2015)

PDL1 expression on monocytes is associated with plasma cytokines in Tuberculosis and HIV
por: Tamene, Wegene, et al.
Publicado: (2021)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
por: Chen, Yundi, et al.
Publicado: (2021)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
por: Patil, Sachin P., et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

In Vivo T Cell Activation Induces the Formation of CD209(+) PDL-2(+) Dendritic Cells
por: Davidson, Matthew G., et al.
Publicado: (2013)

Pdl1 Is a Putative Lipase that Enhances Photorhabdus Toxin Complex Secretion
por: Yang, Guowei, et al.
Publicado: (2012)

Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

The Presence of PDL-1 on CD8+ Lymphocytes Is Linked to Survival in Neonatal Sepsis
por: Akhmaltdinova, Lyudmila L., et al.
Publicado: (2022)

What role does PDL1 play in EMT changes in tumors and fibrosis?
por: Zhang, Yun-Chao, et al.
Publicado: (2023)

Circ_0001946 Promotes the Development of Acute Myeloid Leukemia by Upregulating PDL1
por: Li, Guohui, et al.
Publicado: (2023)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the Absence of Tissue Restricted Antigens
por: Fergusson, Joannah R., et al.
Publicado: (2019)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_btkennl6giqgrs9lnppd81u3f9